Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ablynx Earns Novartis Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ablynx Earns Novartis Milestone

FDA approves IND for Phase I Nanobody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ablynx has received a $533,600 milestone payment triggered by the approval of an IND application for the Phase I trial for a Nanobody licensed to Novartis. This is the first development candidate resulting from the licensing agreement between the two companies from July 2010. Under the agreement, Novartis obtained licenses to develop and commercialize Nanobodies against two targets.

Since July 2010, Novartis has full responsibility for the continued development of both programs and Ablynx is eligible to receive development-based milestone payments and royalties on sales following commercialization of the products.

Dr. Edwin Moses, chief executive officer and chairman of Ablynx, said, “We are excited that Novartis has obtained IND approval and that they will bring this first Nanobody into clinical development in an oncology setting. This development candidate demonstrates the power of the Nanobody platform in addressing complex target classes that are challenging to address with conventional antibodies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters